Present:  Drs. Wetmur, Bishop, Daefler, Palese, Simon, TenOever; Mr. Hauck & Tranchina; Ms. Strauss.

Present via teleconference:  Ms. Erlitz.

Also Present:  Drs. Lowen & Palese; Ms. Schneier.

1. The Committee recapped previous discussions of H1N1 studies, including the decisions made at the May 1, 2009 IBC meeting to:
   •  Conduct swine influenza studies in the EPF on Annenberg 17 following decontamination from current studies.
   •  Conduct guinea pig transmission studies in Icahn. The CDC has posted H1N1 as a biosafety level 2 virus. Mount Sinai investigators will take additional precautions by following level 3 procedures in the BSL2 facility.

The Committee confirmed its support for these strategies.

2. The Committee received confirmation that creation of a recombinant strain of H1N1 with Tamiflu resistance would require RAC approval. In contrast, naturally occurring mutants may be studied without RAC approval. The Committee voted to proceed with studies of naturally occurring mutants. Drug treatment for exposure is recommended.

3. The Committee discussed the importance of avoiding movement of animals between facilities. Guinea pigs will be housed in Icahn and mice will be housed on Annenberg 17. A protocol is in place for delivery of the virus to Annenberg 17, and a protocol will be written for delivery to Icahn. A freezer will be provided in the Icahn facility.